What this means
This is a plan for a trial that is still signing up people, so no results exist yet. It will test whether a lifestyle program or a senolytic drug changes fat tissue and blood sugar control.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over · 72 older adults with obesity, not yet reported
- Where
- 1 site, including California
The science
- Registered title
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
- Trial ID
- NCT05653258 ↗
- Phase
- PHASE 2 / PHASE 3
- Study type
- interventional
- Conditions
- Obesity, Healthy Lifestyle
- What is tested
- Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
- Sponsor
- Cedars-Sinai Medical Center
- Ages
- 18 Years to no maximum
- Dates
- First posted Dec 16, 2022 · updated Mar 18, 2026
Registry summary
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
Sites (1)
- Cedars Sinai Medical Center, Los Angeles, California, United States